Bioventus Inc.

BVS Healthcare Medical Devices

Bioventus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $568.1 million, down 0.91% from fiscal 2024. In the quarter to June 2026, revenue grew 3.76%, EPS grew 345.5%, free cash flow fell 25.1% and total debt fell 27.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

13.30 0.51 −3.69%
Market cap
$1.2B
P/E
16.4×
Fwd P/E
21.4×
Dividend yield
—
F-score
8/9
Altman Z
1.26
Beneish M
−2.77
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
8 8 8 8

+8 more TTM periods

ROE
22.75% 13.57% 10.98% 3.85%
ROA
7.89% 4.24% 3.22% 1.03%
ROIC
7.34% 7.64% 7.16% 5.41%
Return on Tangible Assets
43.36% 23.15% 16.92% 5.34%
Average Days of Receivables
86.82 76.33 82.44 84.42
Free Cash Flow per Share
1.39 1.50 1.08 0.80
Free Cash Flow
94.29 100.63 72.11 53.47
Other line items

Show all line items

Columns are period end dates